Advertisement

Topics

PureTech Health Inks Deal with Boehringer Ingelheim for Immuno-Oncology

20:00 EDT 16 Apr 2019 | BioSpace

PureTech, which has headquarters in Boston, but is listed in London, signed a research collaboration deal with Germany’s Boehringer Ingelheim. The companies will work to develop novel product candidates using PureTech’s proprietary lymphatic targeting technology for immune modulation.

Original Article: PureTech Health Inks Deal with Boehringer Ingelheim for Immuno-Oncology

NEXT ARTICLE

More From BioPortfolio on "PureTech Health Inks Deal with Boehringer Ingelheim for Immuno-Oncology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...